* prior to study entry the subject got vaccinated with a regimen not included in the list given above. * last anti-sars-cov-2 vaccine dose administered less than one month prior to study entry. * vaccination against a disease other than covid-19 within 2 weeks prior to study entry. only exception: influenza vaccination which is allowed at any time. * subjects with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator. * current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to \>10 mg/day prednisolone. * subject simultaneously participates in another clinical trials or has participated in the past 30 days. * subjects unable to report solicited adverse events. * subject with any contraindications to the vaccines in the trial. a list of contraindications as listed in the summary of medicinal product characteristics (smpc, the fachinformation in germany), if appropriate.

* prior to study entry the subject got vaccinated with a regimen not included in the list given above. * last anti-sars-cov-2 vaccine dose administered less than one month prior to study entry. * vaccination against a disease other than covid-19 within 2 weeks prior to study entry. only exception: influenza vaccination which is allowed at any time. * subjects with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator. * current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to \>10 mg/day prednisolone. * subject simultaneously participates in another clinical trials or has participated in the past 30 days. * subjects unable to report solicited adverse events. * subject with any contraindications to the vaccines in the trial. a list of contraindications as listed in the summary of medicinal product characteristics (smpc, the fachinformation in germany), if appropriate.

prior to study entry the subject got vaccinated with a regimen not included in the list given above. last anti-sars-cov-2 vaccine dose administered less than one month prior to study entry. vaccination against a disease other than covid-19 within 2 weeks prior to study entry. only exception: influenza vaccination which is allowed at any time. subjects with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator. current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to >10 mg/day prednisolone. subject simultaneously participates in another clinical trials or has participated in the past 30 days. subjects unable to report solicited adverse events. subject with any contraindications to the vaccines in the trial. a list of contraindications as listed in the summary of medicinal product characteristics (smpc, the fachinformation in germany), if appropriate.

prior to study entry the subject got vaccinated with a regimen not included in the list given above. last anti-sars-cov-2 vaccine dose administered less than one month prior to study entry. vaccination against a disease other than covid-19 within 2 weeks prior to study entry. only exception: influenza vaccination which is allowed at any time. subjects with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator. current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to >10 mg/day prednisolone. subject simultaneously participates in another clinical trials or has participated in the past 30 days. subjects unable to report solicited adverse events. subject with any contraindications to the vaccines in the trial. a list of contraindications as listed in the summary of medicinal product characteristics (smpc, the fachinformation in germany), if appropriate.

primary vaccination performed with different vaccine products as sole (e.g., covid-19 vaccine janssen) or, 1st and 2nd vaccination doses (heterologous vaccination scheme) participants with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to >10 mg/day prednisolone participation in other interventional trials participants unable to report solicited adverse events participants with any contraindications to the vaccines in the trial at randomisation. a list of contraindications as listed in the summary of medicinal product characteristics (smpc), if appropriate use of drugs with significant interaction with the investigational product according to the smpc or similar documents diseases or findings that may have a significant effect on the target variables and which may therefore mask or inhibit the therapeutic effect under investigation any current sars-cov-2 infection or proven in the preceding 3 months persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator legally incapacitated persons persons held in an institution by legal or official order

primary vaccination performed with different vaccine products as sole (e.g., covid-19 vaccine janssen) or, 1st and 2nd vaccination doses (heterologous vaccination scheme) participants with any significant or uncontrolled disease posing a risk due to vaccination as judged by the investigator current immunosuppressive therapy, for example continuous glucocorticosteroid treatment equivalent to >10 mg/day prednisolone participation in other interventional trials participants unable to report solicited adverse events participants with any contraindications to the vaccines in the trial at randomisation. a list of contraindications as listed in the summary of medicinal product characteristics (smpc), if appropriate use of drugs with significant interaction with the investigational product according to the smpc or similar documents diseases or findings that may have a significant effect on the target variables and which may therefore mask or inhibit the therapeutic effect under investigation any current sars-cov-2 infection or proven in the preceding 3 months persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator legally incapacitated persons persons held in an institution by legal or official order